Published on 17 Mar 2023 on Zacks via Yahoo Finance
Tandem Diabetes (TNDM) Releases Favorable Data on t:slim X2
Tandem Diabetes Care, Inc.TNDM recently announced favorable results from the Pediatric Artificial Pancreas (PEDAP) Clinical Trial, published by the New England Journal of Medicine. The participants of the trial comprised children of two-five years of age, with Type 1 Diabetes.
The outcome showed an increase of nearly three hours per day time in range, in patients using the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology, compared to those using a standard insulin pump or multiple daily injections. All the participants were using a Dexcom G6 Continuous Glucose Monitoring System.
About Control-IQ Technology